SoundBite™ Crossing System Pivotal Peripheral CTO Crossing Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-16

Study Completion Date

2019-01-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is aimed at demonstrating the efficacy and safety of the SoundBite™ Crossing System-Peripheral. The study is intended to demonstrate that the SoundBite™ Crossing System can facilitate the passage of either devices intended to treat a chronic total occlusion (CTO) or additional crossing devices through an infrainguinal CTO into the true lumen.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Study of the SoundBite™ Crossing System in Complex Peripheral CTOs

NCT03933657

Peripheral Arterial Occlusive Disease Chronic Total Occlusion of Artery of the Extremities

WITHDRAWN NA

Soundbite Crossing System Peripheral First in Man

NCT03013088

Peripheral Artery Disease

COMPLETED NA

Treatment of Calcific Total Occlusions in Peripheral Artery Disease

NCT05551780

Chronic Total Occlusion of Artery of the Extremities

RECRUITING NA

The Asahi Intecc PTCA Chronic Total Occlusion Study

NCT02379923

Coronary Artery Disease Coronary Artery Chronic Total Occlusion

COMPLETED NA

CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) Study

NCT00801710

Coronary Artery Disease Coronary Artery Chronic Total Occlusion

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System - Peripheral. The enrollment will consist of up to 100 patients meeting the inclusion/exclusion criteria in order to obtain 90 evaluable patients for efficacy and safety analysis. The primary endpoints will be compared to literature-based performance goals to establish study success.

Objective Performance Goals (OPG) have been obtained from a literature based review. Reports published in the past 10 years were reviewed for both safety and effectiveness in crossing infrainguinal CTO. The studies reviewed generally have one primary composite safety endpoint and one primary efficacy endpoint. Some studies have performed formal hypothesis testing versus a pre-specified performance goal for one or both endpoints.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Total Occlusion of Arteries of the Extremities

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SoundBite™ Crossing System - Peripheral

This is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System with subjects diagnosed with de novo infrainguinal arterial chronic total occlusion(s).

Group Type OTHER

SoundBite™ Crossing System - Peripheral

Intervention Type DEVICE

SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SoundBite™ Crossing System - Peripheral

SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Has symptomatic chronic limb ischemia, requiring treatment of an in:frainguinal artery
2. Has Rutherford Clinical Category of 2-5
3. Is ≥ 18 years old
4. Has life expectancy \> 1 year
5. Is able and willing to provide written informed consent prior to study procedure

Unless otherwise specified, the Investigator performing the procedure bases angiographic inclusion on visual determination of qualification imaging taken at time of procedure.

1. Has evidence of a clinically significant de novo CTO located in a peripheral vessel below the infrainguinal ligament confirmed by angiography at time of procedure.
2. Notwithstanding criteria 1, multilevel CTOs are included as long as the total length from the beginning of the most proximal total occlusion to the end of the most distal total occlusion is less than 40 cm.
3. 100% stenosis by visual estimate of angiography at time of procedure.
4. Has target limb with at least one patent (\<50% stenosis) run-off vessel confirmed by angiography or magnetic resonance angiography at time of procedure.

Exclusion Criteria

1. Has had a previous peripheral bypass that includes the target vessel.
2. Has had a previous intervention on the target CTO (e.g., angioplasty, stent placement), including previous attempt at time of index procedure.
3. History of any vascular procedure on the index limb within the last 30 days requiring clinically driven re-intervention.
4. Has an active infection in the target limb.
5. Subject has any planned major surgical or interventional procedure within 30 days after the study procedure.
6. Has received a kidney transplant.
7. Glomerular Filtration Rate (GFR) of less than 40.
8. Unstable coronary artery disease or other uncontrolled comorbidity.
9. Myocardial infarction or stroke within 2 months prior to baseline evaluation.
10. Subject has positive pregnancy test result in women of child bearing potential or is breast-feeding.
11. Participation in any study of an investigational device, medication, biologic, or other agent during study or within 30 days prior to enrollment that is either a cardiovascular study or could, in the judgment of the investigator, affect the results of this study.
12. Subject in whom antiplatelet, anticoagulant therapy is contraindicated
13. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/ml or known coagulopathy.
14. Known, untreated allergy to contrast agents or medications used during or subsequent to endovascular intervention. Patients with aspirin allergy that have been desensitized are not excluded.
15. History of heparin-induced thrombocytopenia (HIT) that cannot be treated with direct thrombin inhibitors.
16. Any thrombolytic therapy within two weeks prior to enrollment.
17. Psychiatric disorder which in the judgment of the investigator could interfere with provision of informed consent, completion of tests, therapy, follow-up or general study compliance

18. Has significant stenos is or occlusion of inflow tract ( upstream disease) unsuccessfully treated at time of index procedure or presenting symptoms such as embolism confirmed by angiography.
19. Has in a native vessel, a previously stented segment separated by \< 3 cm of angiographically normal vessel from the target CTO.
20. CTOs lacking at least one patent target distal artery (::;SO% diameter stenosis).
21. Has an acute or sub-acute intraluminal thrombus within the target vessel.
22. Aneurysm distal to puncture access site at least twice the reference vessel diameter, located in the index vessel, abdominal aorta, iliac or popliteal.
23. Has perforation, dissection or other injury of the access site or index vessel requiring stenting or surgical intervention prior attempting crossing of the target lesion with SoundBite™ Crossing System.
24. Clinical/angiographic evidence of distal embolization in the index extremity.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No